Aurobindo Pharma's Subsidiary CuraTeQ Biologics Reports Positive Top-Line Results for Omalizumab Biosimilar BP11 Phase 3 Study

Key Highlights

• CuraTeQ Biologics Private Limited, a subsidiary of Aurobindo Pharma Ltd, announced positive top-line results from its Phase 3 study of BP11, an investigational biosimilar to Xolair® (omalizumab).
• The study successfully met all primary endpoints, showing high comparability to the reference product in patients with chronic spontaneous urticaria (CSU) at the 300 mg dose.
• The trial was conducted in 608 patients across approximately 80 sites in seven European countries and India.
• The results support regulatory submissions targeting CSU, allergic asthma, and CRSwNP (Chronic Rhinosinusitis with Nasal Polyps).
• Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India, with a robust product portfolio spread over seven major therapeutic/product areas.